OakChart

Outlook Therapeutics Inc

OTLKHealthcare·Biotechnology·USA·Micro·NASD·Nov 11 • 3:59 PM ET

0.4810+0.0204 (4.43%)
2026-11-12 04:05 CET
Market cap
117.10 USD m
Revenue, TTM
0.01 USD m
Net income, TTM
-20.32 USD m
Free cash flow, TTM
-21.99 USD m
EPS diluted, TTM
-0.15
P/E
-
Compare

Price

OTLK against its 20, 50 and 200-day averages
2050200missearnings
0.501.001.50173.1M346.3MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26OTLKclose 0.4820-day 0.4950-day 0.57200-day 0.660.4852w low

81.0% under the 52-week high of 2.54 on 17 Dec 2025. 52-week low 0.16 on 24 Mar 2026. Last 15 sessions, 46.7% high to low

Volume 0.24× normal · the line is the 50-bar volume average

Profile

OTLK
52-week range, 13% of the way up
0.162.54

Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of ONS-5010/LYTENAVA. Its pipeline includes unmet patient needs, repackaged IV bevacizumab, and anti-VEGF. The company was founded by Pankaj Mohan on January 5, 2010 and is headquartered in Iselin, NJ.

Employees17
IPOJun 14, 2016
Beta0.72
ATR, 14d0.04
Rel volume0.24
Short float16.71%
Insider own12.64%
Inst own28.59%

Snapshot

6 groups

Valuation

Index-
Market Cap117.10M
Enterprise Value124.29M
Income-
Sales-
Book/sh-0.06
Cash/sh0.05
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees17
IPOJun 14, 2016

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B-
P/C10.42
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio0.63
Current Ratio0.81
Debt/Eq-
LT Debt/Eq-
Option/ShortYes / Yes

Earnings

EPS (ttm)-
EPS next Y-0.23
EPS next Q-0.08
EPS this Y73.00%
EPS next Y53.10%
EPS next 5Y-
EPS past 3/5Y33.96% 33.18%
Sales past 3/5Y- -
EPS Y/Y TTM86.28%
Sales Y/Y TTM-
EPS Q/Q90.10%
Sales Q/Q-
EarningsAug 14 BMO
EPS/Sales Surpr.-12.50% -99.07%

Ownership

Insider Own12.64%
Insider Trans61.77%
Inst Own28.59%
Inst Trans20.63%
ROA-
ROE-
ROIC-
Gross Margin-
Oper. Margin-
Profit Margin-
SMA20-2.46%
SMA50-15.91%
SMA200-27.18%
Trades-

Technical

Shs Outstand243.45M
Shs Float212.68M
Short Float16.71%
Short Ratio3.70
Short Interest35.55M
52W High2.54 -81.04%
52W Low0.16 198.57%
Volatility7.89% 9.84%
ATR (14)0.04
RSI (14)43.07
Beta0.72
Rel Volume0.24
Avg Volume9.61M
Volume2,343,049

Performance

Perf Week4.09%
Perf Month-14.69%
Perf Quarter-45.88%
Perf Half Y109.13%
Perf YTD-69.56%
Perf Year-61.21%
Perf 3Y-93.99%
Perf 5Y-98.82%
Perf 10Y-99.92%
Recom1.00
Target Price6.17
Prev Close0.46
Price0.48
Change %4.43%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Jul 27, 2026UpgradeBBTIG ResearchNeutral → Buy$4+731.6%
May 18, 2026DowngradeBBTIG ResearchBuy → Neutral
Aug 29, 2025DowngradeHH.C. WainwrightBuy → Neutral
Aug 28, 2025DowngradeGGuggenheimBuy → Neutral
Dec 02, 2024DowngradeCChardan Capital MarketsBuy → Neutral
Mar 27, 2024UpgradeBBTIG ResearchNeutral → Buy$50+10,295.0%
Feb 15, 2024UpgradeCChardan Capital MarketsNeutral → Buy$3+523.7%
Jan 25, 2024UpgradeGGuggenheimNeutral → Buy
Dec 27, 2023UpgradeCCapitalOneEqual Weight → Overweight$5+939.5%
Aug 31, 2023DowngradeHH.C. WainwrightBuy → Neutral$5 → $1+107.9%

Peers

Mkt cap
TickerCompanyMkt cap
EYPTEyePoint Inc30.74M
OCULOcular Therapeutix Inc1.47B
KLRSKalaris Therapeutics Inc41.50M
KODKodiak Sciences Inc6.87B
OCSOculis Holding AG469.78M
LENZLENZ Therapeutics Inc129.13M
ANNXAnnexon Inc794.34M
IRDOpus Genetics Inc358.58M
ALDXAldeyra Therapeutics Inc39.32M
AURAAura Biosciences Inc792.01M

Insider trading

8 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Sukhtian Ghiath M.DirectorAug 12 '26Buy0.992,525,2522,499,99924,617,320Aug 14 07:52 PM
Sukhtian Faisal GhiathDirectorJul 29 '26Buy1.0595,39899,996220,972Jul 29 03:19 PM
Haddadin Yezan MuntherDirectorJun 02 '26Buy0.8329,00024,14566,167Jun 03 06:03 PM
Sukhtian Ghiath M.DirectorMay 28 '26Buy0.598,539,7095,000,00022,092,068Jun 01 09:30 PM
Sukhtian Faisal GhiathDirectorMay 27 '26Buy0.41122,17450,006125,574May 27 03:29 PM
Haddadin Yezan MuntherDirectorMay 26 '26Buy0.4434,00014,96037,167May 27 03:24 PM
THURMAN RANDY HDirectorMay 26 '26Buy0.435,0002,1455,593May 27 03:20 PM
HILZINGER KURT JDirectorMay 26 '26Buy0.44400,000176,520423,655May 27 03:15 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VXFVanguard Extended Market Index ETFAUM: 30.47B

News

latest 14 of 198
  • Outlook Therapeutics Names Greg DiPasquale Chief Commercial Officer (GlobeNewswire) +6.19%
  • Outlook Therapeutics Highlights What the Appointment of New CFO Kevin Lundquist Means for the Company's Next Chapter in Virtual Investor Discussion (GlobeNewswire)
  • Outlook Therapeutics Submits HCPCS Level II Application to CMS for Permanent J-Code for LYTENAVA (bevacizumab-vikg) (GlobeNewswire)
  • Kodiak Sciences Stock Pops 64% After Eye-Disease Drugs Pass Key Trial (Barrons.com)
  • Outlook Therapeutics Fireside Chat from H.C. Wainwright Conference Now Available On-Demand (GlobeNewswire)
  • Outlook Therapeutics CEO, Bob Jahr, Discusses FDA Approval and Commercial Opportunity for LYTENAVA in Virtual Investor CEO Connect Segment (GlobeNewswire)
  • Outlook Therapeutics Appoints Kevin Lundquist as Chief Financial Officer as It Prepares for U.S. Commercial Launch of LYTENAVA (GlobeNewswire)
  • Outlook Therapeutics CEO, Bob Jahr, Participates in the Virtual Investor "Why Now" On-Demand Conference (GlobeNewswire)
  • Outlook Therapeutics Reports Third Quarter Fiscal Year 2026 Financial Results and Provides Business Update Highlighting FDA Approval of LYTENAVA (GlobeNewswire) -14.90%
  • Why Did OTLK Stock Crash In Pre-Market Today? (Stocktwits) -19.20%
  • Outlook Therapeutics Announces Pricing of $55.0 Million Public Offering of Common Stock and Warrants (GlobeNewswire)
  • Outlook Therapeutics Announces Proposed Public Offering of Common Stock and Warrants (GlobeNewswire)
  • Outlook Therapeutics to Report Third Quarter Fiscal Year 2026 Financial Results and Host a Corporate Update Conference Call and Webcast on August 14, 2026 (GlobeNewswire) -5.58%
  • Outlook Therapeutics Recently Approved Therapy Could Become Preferred Anti-VEGF Treatment Option In $8.5B US Retina Market, Says BTIG (Stocktwits) -24.20%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-08-14-0.090-0.080-0.1500.010.973
2026Q22026-05-15-0.160-0.121-0.0540.134.393
2026Q12026-02-17-0.220-0.227-0.383-1.213.143
2025Q42025-12-19-0.060-0.260-0.160-0.105.845
2025Q32025-08-14-0.440-0.353-0.5451.511.504
2025Q22025-05-15-0.400-0.543-1.5020.000.635
2025Q12025-02-14-0.890-0.7600.7170.000.005
2024Q42024-12-27-0.880-0.8030.2380.000.006
2024Q32024-08-14-0.830-1.033-0.8850.000.007
2024Q22024-05-15-1.550-0.910-8.0090.000.007
2024Q12024-02-14-0.800-0.995-0.8590.000.007
2023Q42023-12-22-1.000-1.150-0.9980.002.498
2023Q32023-08-14-1.600-1.050-1.6100.000.008
2023Q22023-05-15-0.600-1.282-0.5190.000.007
2023Q12023-02-14-1.600-1.190-1.6410.000.003
2022Q42022-12-29-1.200-1.328-1.2620.000.005

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-24.800-31.900-39.6228.152.96
2020FY-9.400-12.800-13.4720.000.16
2021FY-7.000-8.666-6.9640.000.20
2022FY-6.200-5.942-6.2290.000.00
2023FY-4.800-4.800-4.7150.002.18
2024FY-4.060-4.905-4.0630.000.00
2025FY-1.790-1.798-1.4901.416.71
2026FY--0.483--0.68
2027FY--0.227--46.35
2028FY-0.570--268
2029FY-0.950--428
2030FY-0.940--582

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-013011.771.002.82
2026Q4S2026-10-314012.701.005.50
2026Q4S2026-10-074022.701.005.50
2026Q4S2026-09-094122.701.005.50
2026Q4S2026-08-244112.981.005.50
2026Q4S2026-08-174122.981.005.50
2026Q4S2026-08-143113.031.005.50
2026Q4S2026-08-053113.031.005.50
2026Q4S2026-08-023123.031.005.50
2026Q4S2026-07-244128.461.0024.73
2026Q4S2026-07-163029.441.0024.73
2026Q4S2026-06-214027.921.0024.73
2026Q4S2026-06-104037.921.0024.73
2026Q4S2026-05-234028.821.0024.73

Estimate history

EPS, annual-288-194.715-39.622-13.472-6.964-6.229-4.715-4.063-1.794
Period201720182019202020212022202320242025
EPS, quarterly-8.009-0.8850.2380.717-1.502-0.545-0.383-0.054-0.149
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q1 '26Q2 '26Q3 '26
Sales, annual3.8123.0888.146000001.414
Period201720182019202020212022202320242025
Sales, quarterly000001.505-1.2080.1270.009
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q1 '26Q2 '26Q3 '26
Shares, annual0.1560.4511.436.3598.82311.36613.01323.90653.887187.097
Period201720182019202020212022202320242025MRQ
Shares, quarterly22.01323.40623.90624.90632.90743.47964.557104.614187.097
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.011.410.000.000.000.000.008.153.09
Cost of Goods Sold Incl. D&A0.030.760.110.040.200.260.55--
Gross Profit-0.020.66-0.11-0.04-0.20-0.26-0.55--
Selling, General and Administrative Excl. Other10.7967.7271.5953.0862.8752.0134.4229.3325.48
Research and Development3.2527.7841.7626.4542.3338.9626.3423.8118.50
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-10.81-67.06-71.70-53.13-63.07-52.27-34.97-24.54-25.44
Interest Expense-0.283.161.561.490.941.763.473.89
Unusual Expense9.47-3.421.314.281.44-0.091.789.924.40
Net Income Before Taxes-20.32-63.98-75.36-58.98-66.05-53.16-38.51-37.93-33.74
Income Taxes0.00-1.550.000.000.000.00-3.27-3.41-3.65
Consolidated Net Income-20.32-62.42-75.37-58.98-66.05-53.16-35.24-34.59-46.11
Net Income From Continuing Operations-20.32-62.42-75.37-58.98-66.05-53.16-35.24-34.59-46.11
Net Income-20.32-62.42-75.37-58.98-66.05-53.16-48.87-36.04-48.02
EPS (Recurring)-0.10-1.86-4.01-4.48-6.13-6.97-13.13-31.98-182.21
EPS (Basic, Before Extraordinaries)-0.15-1.79-4.06-4.72-6.23-6.96-13.47-39.62-194.72
EPS (Diluted)-0.15-1.79-4.06-4.72-6.23-6.96-13.47-39.62-194.72
EBITDA-10.80-66.94-71.59-53.08-62.87-52.01-34.42-21.18-22.39
Non-Operating Income (Expense)-0.04-0.050.81-0.01-0.05-0.050.000.000.00
Other After Tax Adjustments0.000.000.000.000.000.000.00-0.06-16.02
Stock Option Compensation Expense0.796.644.254.386.093.572.050.961.57
Price To Sales Ratio-26.09-----3.3312.52
Gross Margin-46.49-------
Operating Margin--4,744.25------301.29-824.09
Net Margin--4,416.22------442.41-1,555.24
Shares Outstanding187.1053.8923.9113.0111.378.826.361.430.45
Market Capitalization117.10117.10126.3257.17277.32382.9291.5742.6370.75

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q32025Q22025Q12024Q42024Q3
Total Revenue0.010.13-1.211.510.000.000.000.00
Cost of Goods Sold Incl. D&A0.030.180.060.470.030.030.030.03
Gross Profit-0.02-0.05-1.271.04-0.03-0.03-0.03-0.03
Selling, General and Administrative Excl. Other10.7913.9712.2216.7812.3621.5822.8519.53
Research and Development3.254.503.637.134.419.6612.5211.20
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-10.81-14.03-13.48-15.75-12.39-21.61-22.88-19.56
Interest Expense---0.050.02---
Unusual Expense9.47-9.629.544.3233.91-38.97-28.34-63.62
Net Income Before Taxes-20.32-4.45-23.06-20.15-46.3517.385.6944.41
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-20.32-4.45-23.06-20.15-46.3617.385.6944.41
Net Income From Continuing Operations-20.32-4.45-23.06-20.15-46.3617.385.6944.41
Net Income-20.32-4.45-23.06-20.15-46.3617.385.6944.41
EPS (Recurring)-0.10-0.14-0.27-0.46-0.73-0.41-0.59-2.63
EPS (Basic, Before Extraordinaries)-0.15-0.05-0.38-0.55-1.500.720.241.91
EPS (Diluted)-0.15-0.05-0.38-0.55-1.500.720.24-0.89
EBITDA-10.80-14.00-13.45-15.72-12.36-21.58-22.85-19.53
Non-Operating Income (Expense)-0.04-0.05-0.04-0.03-0.040.020.220.35
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.790.760.881.321.352.901.111.10
Price To Sales Ratio---39.28----
Gross Margin-253.52-41.04104.9468.83----
Operating Margin-124,255.28-11,006.821,116.38-1,046.20----
Net Margin-233,554.85-3,494.281,909.05-1,338.75----
Shares Outstanding187.10104.6164.5643.4832.9124.9123.9123.41
Market Capitalization117.1017.4170.1868.5739.8047.07126.32172.73

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments8.0814.9323.3917.4014.4812.548.021.723.19
Short Term Receivables1.490.000.000.000.000.000.000.000.00
Inventories3.340.000.000.000.000.000.000.000.00
Other Current Assets4.4812.497.5910.127.035.415.491.590.72
Total Current Assets17.3927.4230.9827.5221.5117.9413.503.303.90
Net Property, Plant & Equipment0.230.270.030.070.280.493.1818.4916.09
Total Investments and Advances0.550.690.790.800.850.900.000.000.00
Other Assets0.420.440.500.130.170.390.460.490.74
Total Assets18.5828.8232.3028.5322.8119.7317.1322.2820.73
Short Term Debt Incl. Current Port. of LT Debt30.0129.4935.5610.950.973.8811.5318.385.01
Accounts Payable10.197.976.573.492.202.392.283.6110.95
Income Tax Payable0.301.861.861.861.861.861.861.862.35
Other Current Liabilities5.313.242.753.431.737.764.628.2010.43
Total Current Liabilities45.8142.5546.7319.736.7515.8920.2932.0428.74
Long Term Debt0.190.250.000.0010.930.953.423.5513.41
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Other Liabilities4.7759.100.010.060.520.074.207.509.31
Total Liabilities50.77101.9046.7419.7918.2016.9127.9043.0951.46
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.005.364.732.92
Common Equity-32.19-73.08-14.448.744.612.83-16.13-25.54-33.65
Total Shareholders Equity-32.19-73.08-14.448.744.612.83-10.77-20.81-30.73
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity-32.19-73.08-14.448.744.612.83-10.77-20.81-30.73
Total Liabilities & Stockholders Equity18.5828.8232.3028.5322.8119.7317.1322.2820.73
Book Value Per Share-0.60-3.06-1.110.770.520.44-11.28-56.59-215.94
Tangible Book Value Per Share-0.60-3.06-1.110.770.520.44-11.28-56.59-215.94
Full-Time Employees1723241798145648
Price to Book Ratio-8.66-1.49-10.3931.7483.1132.40-2.64-5.36-1.17
Return on Assets-263.36-246.60-193.93-257.32-249.92-191.17-175.48-214.40-180.14
Return on Equity----989.99-1,430.33----
Return on Invested Capital----755.67-342.19-934.00---
Quick Ratio0.310.640.661.393.191.130.670.100.14
Current Ratio0.380.640.661.393.191.130.670.100.14

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-20.32-62.42-75.37-58.98-66.05-53.16-35.24-34.52-30.09
Depreciation0.010.120.110.040.200.260.553.363.05
Other Funds (Non Cash)9.325.629.4811.2110.865.734.1712.077.68
Funds from Operations-10.98-56.69-65.78-47.73-54.99-47.17-30.52-19.10-19.36
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-11.014.86-3.024.75-1.68-7.08-1.27-13.19-13.68
Income Taxes Payable--1.55---0.00-0.000.00-0.50
Cash from Operating Activities-21.99-51.83-68.79-42.97-56.67-54.25-31.79-32.29-33.04
Capital Expenditures0.000.000.000.000.000.000.00-0.44-2.78
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00-
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.00-
Purchase or Sale of Investments-2.100.000.000.000.000.00-0.900.000.00
Purchase of Investments-2.100.000.000.000.000.00-0.900.00-
Sale Or Maturity of Investments0.000.000.000.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-2.100.000.000.000.000.00-0.90-0.44-2.78
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00---
Change in Capital Stock27.5848.0360.3330.0262.5149.9036.5745.9735.34
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.00-1.09
Sale of Common Pref Stock27.5848.0360.3330.0262.5149.9036.5745.9736.43
Proceedsfrom Stock Options23.2725.4060.3330.0262.3146.3035.4345.9636.43
Issuance or Reduction of Debt, Net0.00-3.04-0.0018.94-2.926.300.64-6.94-0.99
Change in Long Term Debt0.00-3.04-0.0018.94-2.926.300.64-6.94-0.99
Issuance of Long Term Debt-17.0033.100.0029.189.409.990.900.000.00
Reduction of Long Term Debt17.00-36.14-0.00-10.23-12.32-3.69-0.26-6.94-0.99
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.000.00
Cash from Financing Activities27.5844.9860.3348.9759.5956.1937.2139.0334.35
Net Change in Cash3.49-6.84-8.466.002.921.944.526.30-1.47
Free Cash Flow-21.99-51.83-68.79-42.97-56.67-54.25-31.79-32.73-35.82
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q32025Q22025Q1
Cash & Short Term Investments11.247.758.688.907.565.70
Short Term Receivables1.642.720.111.750.000.00
Inventories5.043.343.464.133.603.11
Other Current Assets5.247.094.926.326.656.86
Total Current Assets23.1720.9017.1721.1017.8115.67
Net Property, Plant & Equipment0.190.200.210.240.250.26
Total Investments and Advances2.530.470.510.590.620.66
Other Assets0.300.320.350.460.390.42
Total Assets26.1821.8918.2422.3919.0817.01
Short Term Debt Incl. Current Port. of LT Debt18.2915.9136.7214.0612.0530.80
Accounts Payable6.8113.647.3210.267.7712.19
Income Tax Payable0.300.300.301.861.861.86
Other Current Liabilities3.289.044.715.313.153.39
Total Current Liabilities28.6838.8849.0631.4924.8248.24
Long Term Debt0.1411.280.1720.6421.260.23
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities7.760.727.567.455.4518.83
Total Liabilities36.5850.8956.7959.5851.5467.30
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity-10.39-28.99-38.55-37.19-32.46-50.29
Total Shareholders Equity-10.39-28.99-38.55-37.19-32.46-50.29
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity-10.39-28.99-38.55-37.19-32.46-50.29
Total Liabilities & Stockholders Equity26.1821.8918.2422.3919.0817.01
Book Value Per Share-0.06-0.28-0.60-0.86-0.99-2.02
Tangible Book Value Per Share-0.06-0.28-0.60-0.86-0.99-2.02
Price to Book Ratio-8.66-0.34-1.85-1.62-0.60-0.62
Return on Assets----125.0454.08-241.97
Quick Ratio0.630.450.280.540.570.26
Current Ratio0.810.540.350.670.720.32

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q32025Q22025Q1
Net Income-20.32-4.45-23.06-20.15-46.3617.38
Depreciation0.010.030.030.030.030.03
Other Funds (Non Cash)9.32-8.8210.466.0435.67-35.26
Funds from Operations-10.98-13.24-12.57-14.09-10.66-17.86
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-11.015.41-2.372.19-5.926.89
Cash from Operating Activities-21.99-7.83-14.94-11.90-16.58-10.97
Capital Expenditures0.000.000.000.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments-2.100.000.000.000.000.00
Purchase of Investments-2.100.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-2.100.000.000.000.000.00
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock27.586.9015.5314.1518.251.74
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock27.586.9015.5314.1518.251.74
Proceedsfrom Stock Options23.276.9014.9314.151.421.74
Issuance or Reduction of Debt, Net0.000.000.00-0.910.190.00
Change in Long Term Debt0.000.000.00-0.910.190.00
Issuance of Long Term Debt-17.0017.000.000.0033.100.00
Reduction of Long Term Debt17.00-17.000.00-0.91-32.910.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities27.586.9015.5313.2518.441.74
Net Change in Cash3.49-0.930.591.341.85-9.22
Free Cash Flow-21.99-7.83-14.94-11.90-16.58-10.97

Revenue breakdown

Biological Products, (No Diagnostic Substances)2025: 1.41M
United States2025: 1.41M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3016.71%35.5M212.7M10.17M
2026-10-1515.32%32.6M212.7M12.85M
2026-09-3016.22%31.9M196.7M13.65M
2026-09-1516.38%32.2M196.7M15.61M
2026-08-3116.73%32.9M196.7M18.49M
2026-08-149.36%19.9M212.6M25.01M
2026-07-3113.19%20.0M151.8M21.80M
2026-07-157.40%11.2M151.9M19.54M
2026-06-3010.60%14.0M132.3M18.56M
2026-06-1510.27%13.6M132.3M16.62M
2026-05-2935.88%16.1M45.0M13.21M
2026-05-1513.02%9.1M69.8M3.66M
2026-04-306.31%6.4M102.0M3.23M
2026-04-156.46%4.7M72.5M2.67M
2026-03-314.39%3.2M72.5M5.04M
2026-03-135.52%3.2M57.6M5.52M
2026-02-276.41%3.7M57.6M5.64M
2026-02-137.81%4.5M57.6M6.21M
2026-01-3010.24%4.6M44.5M6.81M
2026-01-1511.54%4.8M42.0M6.55M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call0.500.000.050.051.7761,7662020.654-0.0090.000
call1.000.000.050.014.9501,6310.000.297-0.0070.000
call1.500.000.300.056.4432,1280.000.263-0.0090.000
call2.000.000.050.447.3121,3590.000.249-0.0090.000
call2.500.000.100.047.9393010.000.236-0.0100.000
call5.000.000.100.309.72829.000.000.214-0.0120.000
call7.500.000.050.0510.33119.000.000.211-0.0110.000
put0.500.000.300.1510.6498720.00-0.383-0.0070.000
put1.000.050.750.4811.4113570.00-0.702-0.0070.000
put1.500.551.551.000.0001020.00-0.737-0.0090.000
put2.001.052.051.230.00078.000.00-0.754-0.0100.000
put2.501.652.401.8721.3371220.00-0.764-0.0100.000
put5.004.005.104.800.0000.000.00-0.786-0.0110.000
put7.506.407.707.300.0000.000.00-0.795-0.0120.000

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-10-13SCHEDULE 13GSEC
2026-09-308-KCurrent report2026-09-25SEC
2026-09-188-KCurrent report2026-09-16SEC
2026-09-024Statement of changes in beneficial ownership of securities2026-09-01SEC
2026-09-023Initial statement of beneficial ownership of securities2026-09-01SEC
2026-08-278-KCurrent report2026-08-23SEC
2026-08-19SCHEDULE 13GSEC
2026-08-1810-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-17NT 10-Q2026-06-30SEC
2026-08-144Statement of changes in beneficial ownership of securities2026-08-14SEC
2026-08-144Statement of changes in beneficial ownership of securities2026-08-14SEC
2026-08-148-KCurrent report2026-08-12SEC
2026-08-14424B5SEC
2026-08-148-KCurrent report2026-08-14SEC
2026-08-14SCHEDULE 13D/ASEC
2026-08-144Statement of changes in beneficial ownership of securities2026-08-12SEC
2026-08-12424B5SEC
2026-08-128-KCurrent report2026-08-12SEC
2026-07-294Statement of changes in beneficial ownership of securities2026-07-29SEC
2026-07-248-KCurrent report2026-07-24SEC
2026-07-248-KCurrent report2026-07-21SEC
2026-07-234Statement of changes in beneficial ownership of securities2026-07-21SEC
2026-07-234Statement of changes in beneficial ownership of securities2026-07-21SEC
2026-07-21EFFECTEffectiveness filing by commission orderSEC
2026-07-21424B3SEC
2026-07-17S-3Registration statement for specified transactions by certain issuers including face-amount certificate companiesSEC
2026-07-168-KCurrent report2026-07-16SEC
2026-07-10DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-07-08DRSSEC
2026-06-268-KCurrent report2026-06-26SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-082.50M100
2026-07100.00K100
2026-0624.15K100
2026-055.24M500
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
VANGUARD CAPITAL MANAGEMENT LLC2.73%
PERCEPTIVE ADVISORS LLC1.96%
UBS Group AG1.37%
MARSHALL WACE, LLP1.24%
BlackRock, Inc.1.04%
JANE STREET GROUP, LLC0.89%
GEODE CAPITAL MANAGEMENT, LLC0.71%
SUSQUEHANNA INTERNATIONAL GROUP, LLP0.60%
HRT FINANCIAL LP0.49%
VANGUARD FIDUCIARY TRUST CO0.41%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND1.92%
VANGUARD EXTENDED MARKET INDEX FUND0.77%
Fidelity Extended Market Index Fund0.22%
Fidelity Total Market Index Fund0.08%
Fidelity Series Total Market Index Fund0.07%
VANGUARD INSTITUTIONAL TOTAL STOCK MARKET INDEX FUND0.03%
VANGUARD BALANCED INDEX FUND0.02%
Fidelity Nasdaq Composite Index Fund0.01%
Knights of Columbus U.S. ALL CAP INDEX FUND0.00%
Blackstone Alternative Multi-Strategy Fund0.00%

OakChart. OTLK. Cached 15 minutes.